Welcome to our dedicated page for IGC Pharma SEC filings (Ticker: IGC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
IGC Pharma, Inc. filings document a clinical-stage biotechnology issuer with common stock listed on NYSE American under the symbol IGC. The company's regulatory disclosures cover material-event reports, operating and financial results, clinical and regulatory updates tied to Alzheimer's disease programs, and capital-structure matters including promissory note financing and authorized share changes.
Form 8-K disclosures also record amendments to governing documents, the fiscal year-end change to December 31, shareholder voting results, board election and auditor ratification matters, and equity incentive share approvals. These filings frame the company's governance, financing arrangements, reporting calendar and development-stage disclosure profile.
IGC Pharma (IGC) reported results from its 2025 Annual Meeting held on October 10, 2025. Stockholders elected Ram Mukunda and James Moran as Class C directors to serve until the 2028 annual meeting and ratified Manohar Chowdhry & Associates as the independent auditor for the 2026 fiscal year.
Shareholders approved the grant of 5,000,000 shares of common stock to be issued from time to time to employees, advisors, directors, and consultants based on board- or CEO-set performance, vesting, and incentive metrics. They also approved an amendment to increase authorized common stock from 150,000,000 to 600,000,000 shares. A non-binding advisory vote set the frequency of say-on-pay votes at every three years.
Participation was strong, with 53,776,307 shares voted, representing approximately 59.22% of the 90,809,112 shares outstanding and entitled to vote. Broker non-votes totaled 18,341,638.
IGC Pharma, Inc. reported that its wholly owned subsidiary Holi Hemp LLC, doing business as HH Processors, entered into a Sale of Assets and Manufacturing Agreement with Wellness Essentials Northwest Inc. The Buyer will acquire equipment, inventory, and a ready-to-move facility and assume employee, utility, lease, and other operating obligations.
The parties agreed on a fair value of approximately $2.7 million, subject to an auditor’s valuation review. Holi Hemp will receive preferential supply rights, and if the Buyer disposes of the operating business within five years, Holi Hemp is entitled to 10% of the net proceeds from that sale, all subject to customary closing conditions and internal approvals.
IGC Pharma, Inc. prospectus supplement describes securities the company may offer and highlights capital needs and risks tied to its drug and hemp-related businesses. The company has reserved millions of shares for incentive plans, restricted stock, and unit conversions and disclosed a September 2024 share purchase agreement for 588,235 shares at a total of $200,000. The document lists primary uses of proceeds, including working capital, funding pre-clinical and clinical trials for IGC-AD1 and TGR-63, AI development to streamline trials, lab and GMP facility development, marketing, patent filings and potential acquisitions. Key risk factors include funding sufficiency, regulatory approvals (including FDA INDA and Phase 2 trials), reliance on third parties for trials and manufacturing, intellectual property protection, market acceptance of phytocannabinoid/hemp-based products, geopolitical and economic conditions across multiple regions, and data security or IT disruptions.
IGC Pharma, Inc. proxy materials disclose details of the company’s equity plans, insider trading rules, and Audit Committee review for Fiscal 2025. Equity compensation plans approved by security holders show 13,823,529 shares available, representing 15.21% (figures presented in the filing). The filing cautions that future equity issuances could dilute market price, earnings per share, and book value per share if shares are issued below market or via low conversion prices. The company states it did not grant any stock options, SARs, or similar option-like instruments in Fiscal 2025. The Insider Trading Policy applies to directors, officers, employees and is filed as Exhibit 19.1. The Audit Committee reviewed audited financial statements with management, discussed required matters and auditor independence with Manohar Chowdhry & Associates, and recommended inclusion of the audited financial statements in the Annual Report for Fiscal 2025.
IGC Pharma (NYSE:IGC) filed its Form 10-K for the fiscal year ended March 31 2025. The company remains a non-accelerated, smaller reporting company with 83.9 million common shares outstanding and an aggregate non-affiliate market value of $29.7 million as of Sept 30 2024.
Management reiterates its mission to advance IGC-AD1—now in Phase 2 clinical trials for Alzheimer’s agitation—while investing in an AI-driven early-diagnosis platform. The filing lists extensive risk factors covering cash sufficiency, regulatory approvals, IP protection, clinical-trial funding, and cybersecurity. No restatements, auditor ICFR attestation, or material acquisitions/dispositions were disclosed. Standard sections (MD&A, financials, controls) are included, and the company confirms timely SEC compliance.